Emery, Paul
Van Keep, Marjolijn
Beard, Steve
Graham, Chris
Miles, LaStella
Jugl, Steffen Marc
Gunda, Praveen
Halliday, Anna
Marzo-Ortega, Helena
Funding for this research was provided by:
Novartis Pharmaceuticals UK Limited
Article History
First Online: 25 May 2018
Compliance with Ethical Standards
:
: Marjolijn Van Keep, Steve Beard, Chris Graham and LaStella Miles declare they have no conflicts of interest. Marjolijn Van Keep and Steve Beard are employees of BresMed Health Solutions, and Chris Graham and La Stella Miles are employees of RTI Health Solutions; these organisations were contracted by Novartis Pharmaceuticals UK Ltd to undertake part of the work. Steffen Marc Jugl is an employee of Novartis Pharma AG, Basel, Switzerland, and owns stock and stock options in Novartis Pharma AG, Basel, Switzerland. Praveen Gunda is an employee of Novartis Healthcare Private Limited, Hyderabad, India. Anna Halliday is an employee of Novartis Pharmaceuticals UK Limited, Camberley, UK. Helena Marzo-Ortega has received grants from Janssen and Pfizer, and honoraria for speaking arrangements/advisory boards from AbbVie, Celgene, Janssen, Eli Lilly & Co, MSD, Novartis, Pfizer and UCB. Paul Emery has undertaken clinical trials and provided expert advice to Pfizer, MSD, AbbVie, BMS, UCB, Roche, Novartis, Samsung, Sandoz and Eli Lilly & Co.
: This study was funded by Novartis Pharmaceuticals UK Ltd, Camberley, UK.
: The datasets used for the cost-effectiveness analysis are not publicly available, but may be available from the corresponding author on reasonable request.